Company Overview - Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of small molecule medicines using targeted protein degradation (TPD) [5] - The company aims to address critical health problems and improve patients' lives by deploying TPD to target disease pathways that are inaccessible with conventional therapeutics [5] - Kymera has advanced its first degrader into clinical trials for immunological diseases and is also developing oncology programs targeting undrugged or poorly drugged proteins [5] Recent Financial Activity - Kymera Therapeutics announced the closing of an upsized underwritten public offering totaling $225 million, which included common stock and pre-funded warrants [1] - The company sold 2,830,533 shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares at a price of $40.7499 each [1] - The gross proceeds from the offering were approximately $258.75 million before deducting underwriting discounts and commissions [1] Underwriters and Regulatory Compliance - Morgan Stanley, J.P. Morgan, TD Cowen, and Stifel acted as joint book-running managers for the offering [2] - The securities were offered under an automatically effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [3]

Kymera Therapeutics, Inc. (KYMR) announced the pricing of its underwritten public offering of $225 million of shares of its common stock. The company is selling approximately 2 million shares of common stock at a public offering price of $40.75 per share. In addition, it is selling pre-funded warrants to purchase 3.5 million shares in the offering in lieu of common stock to certain investors. The pre-funded warrants are being sold at a public offering price of $40.7499 per pre-funded warrant. This offering ...

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 2,002,313 shares of common stock and, in lie ...

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warra ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants Justine Koenigsberg - Vice President, Investor Relations Nello Mainolfi - Founder, President & CEO Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Eric Joseph - J.P. Morgan Jeff Jones - Oppenheimer Kelly Shi - Jefferies Vikram Purohit - Morgan Stanley Brad Canino - Stifel Nicolaus Marc Frahm - TD Cowen Kalpit Patel - B. Riley Paul Je ...

Kymera Therapeutics, Inc. (KYMR) reported a loss of 58 cents per share in the second quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 69 cents. In the year-ago quarter, Kymera reported a loss of 67 cents per share. Loss narrowed in the quarter due to higher revenues. Collaboration revenues totaled $25.6 million, which beat the Zacks Consensus Estimate of $12 million. The reported figure increased 55.3% from the year-ago quarter's level. Collaboration revenues in the second quarter we ...

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.67 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 15.94%. A quarter ago, it was expected that this company would post a loss of $0.73 per share when it actually produced a loss of $0.69, delivering a surprise of 5.48%. Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------- ...

Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following interim analysis of safety and efficacy data STAT6 degrader program on track to initiate Phase 1 in second half of 2024 with data in first half of 2025; TYK2 degrader program on track to initiate and complete Phase 1 in 2025 Data from KT-253 (MDM2) and KT-333 ( ...

Michael Lutz/iStock via Getty Images Kymera entered a collaboration agreement with the French Pharma giant Sanofi (SNY) in July 2020, involving two biological targets, IRAK4, and an undisclosed target - according to Kymera's Q1 2024 quarterly report / 10Q submission: With respect to both targets, Sanofi is responsible for development, manufacturing, and commercialization of product candidates after a specified development milestone occurs with respect to each collaboration candidate. Kymera Immunology Oral ...